Eyenovia (EYEN)
(Real Time Quote from BATS)
$0.74 USD
0.00 (0.35%)
Updated Jun 5, 2024 02:44 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Eyenovia, Inc. [EYEN]
Reports for Purchase
Showing records 61 - 80 ( 83 total )
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroProst Indication Expanded; Phase 3 to Start in 1H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroPine IND Application Accepted; Phase 3 to Start in 1H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MIST-1 Validates Platform; MIST-2 Also Likely to be Positive
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroStat MIST-1 Phase 3 Study Reports Positive Reiterate Buy and Raising PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
New Clinical Data Support the Use of Low-Dose Atropine in Myopia Progression; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroStat MIST-1 Study Completes Enrollment; MIST-2 Enrolls First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Micro-dose Latanoprost Phase 2 Results Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroStat Phase 3 Trials Enroll First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Results Reported; Phase 3 Trials Initiation Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Reinventing Topical Delivery of Ocular Therapeutics; Initiating With Buy Rating and $12 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eyenovia, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Unclassified
Company: Eyenovia, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Unclassified
Company: Eyenovia, Inc.
Industry: Unclassified
Company: Eyenovia, Inc.
Industry: Unclassified
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eyenovia, Inc.
Industry: Unclassified
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.